Skip to main content

Faculty Profile

gonzales-luna-anneAnne J. Gonzales-Luna

Research Assistant Professor
Department of Pharmacy Practice and Translational Research

Office: Health 2
University of Houston College of Pharmacy
4849 Calhoun, Room 4033
Houston, TX 77204-5039

Contact: ajgonzales-luna@uh.edu - 713-743-0212

Research:

  • Clostridioides difficile infection
  • Microbiome
  • Clinical pharmacy
  • Multidrug resistant infections
  • Board Certified Infectious Diseases Pharmacist (BCIDP), Board of Pharmacy Specialties
  • Post-Doctoral Fellowship – Infectious Diseases, The University of Houston College of Pharmacy
  • PGY-1 Pharmacy Practice Residency, Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)
  • Doctor of Pharmacy, with Honors, The University of Texas at Austin College of Pharmacy
  • B.A. in Biology, with Honors, The University of Texas at Austin
  • Business Foundations Program Certificate, with High Distinction, The University of Texas at Austin

MyNCBI Profile
  • Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021; [ePub ahead of print]
  • Gonzales-Luna AJ, Spinler JK, Oezguen N, Khan Md AW, Danhof HA, Endres BT, Alam MJ, Begum K, Lancaster C, Costa GPD, Savidge TC, Hurdle JG, Britton R, Garey KW. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021; 70:102387 [ePub ahead of print]
  • Carlson TJ, Gonzales-Luna AJ, Nebo K, Chan HY, Tran N-L T, Antony S, Lancaster C, Alam MJ, Begum K, Garey KW. Assessment of Kidney Injury as a Severity Criteria for Clostridioides difficile Infection. Open Forum Infect Dis. 2020; 7(11):ofaa476.
  • Garey KW, Begum K, Lancaster C, Gonzales-Luna AJ, Bui D, Mercier J, Corinne, SY, Ducharme MP, Hu M, Vince B, Silverman MH, Alam MJ, Kankam M. Randomized, Double blind, Placebo controlled, Single and Multiple Ascending Dose Phase 1 Study to Determine the Safety, Pharmacokinetics, Food, and Fecal Microbiome Effects of Ibezapolstat Administered Orally to Healthy Subjects. J Antimicrob Chemother. 2020; 75(12):3635-43.
  • Bassères E, Begum, K, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Miranda J, Rashid T, Alam MJ, Eyre DW, Wilcox MH, Garey KW. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020; 75(10):2879-84.
  • Begum K, Bassères E, Miranda J, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Rashid T, Eyre DW, Wilcox MH, Alam MJ, Garey KW. In vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators Against Clostridioides difficile. Antimicrob Agents Chemother. 2020; 64(8):e00522-20.
  • Gonzales-Luna AJ, Carlson TJ. Follow your gut: Microbiome-based approaches in the developmental pipeline for the prevention and adjunctive treatment of Clostridioides difficile infection (CDI). Curr Infect Dis Rep. 2020; 22(22).
  • Carlson TJ, Gonzales-Luna, AJ. Utilizing antibiotics to prevent Clostridioides difficile infection: Does exposure to a risk factor decrease risk? J Antimicrob Chemother. 2020; 75(10):2735-42.
  • Carlson TJ, Endres BT, Pham JL, Gonzales-Luna AJ, Alnezary FS, Nebo K, Miranda J, Lancaster C, Bassères E, Begum K, Alam MJ, Reveles KR, Garey KW. Eosinopenia and binary toxin increases mortality in hospitalized patients with Clostridioides difficile infection. Open Forum Infect Dis. 2020; 7(1):ofz552
  • Gonzales-Luna AJ, Carlson TJ, Dotson KM, Poblete K, Costa G, Miranda J, Lancaster C, Walk ST, Tupy S, Begum K, Alam MJ, Garey KW. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infec. 2020; 9(1):341-7.
  • Reveles KR, Dotson KM, Gonzales-Luna A, Surati D, Endres BT, Alam MJ, Garey KW. Clostridioides (formerly Clostridium) difficile infection during hospitalization increases the likelihood of non-home patient discharge. Clin Infect Dis. 2018; 68(11):1887-93.

Presentations

  • Updates in the Prevention and Treatment of Recurrent Clostridioides difficile Infection: Focus on High-Risk Populations, ASHP live webinar, November 2020
  • Prevention and Treatment of Recurrent Clostridioides difficile Infection: A Call to Action, ASHP Midyear Annual Meeting 2019, Las Vegas, NV
  • Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in Clostridioides difficile [Oral abstract], IDWeek 2019, Washington, D.C.